Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST LTE long-term extension of litifilimab in active cutaneous lupus erythematosus
jRCT2041240127Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of litifilimab in cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE), sponsored by Biogen. Primary endpoint: Number of participants with treatment-emergent adverse events and serious adverse events. Started Nov 2024; status: recruiting.
02
Drugs
litifilimab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on jRCT2041240127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240127.